UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
(Exact name of registrant as specified in its charter)
| (State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||
(Address of principal executive offices) (Zip Code)
(650 ) 521-8000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) | |||||
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||||||||
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o
ITEM 5.02. DEPARTURE OF DIRECTORS OR CERTAIN OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF CERTAIN OFFICERS; COMPENSATORY ARRANGEMENTS OF CERTAIN OFFICERS.
On October 13, 2023, the Board (the “Board”) of Pacific Biosciences of California, Inc. (the “Company”) increased the size of the Board to ten directors and, upon the recommendation of its Corporate Governance and Nominating Committee, appointed David Meline to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders.
There are no arrangements or understandings between Mr. Meline, on the one hand, and the Company or any other persons, on the other hand, pursuant to which Mr. Meline was selected as a director. There are no related party transactions between the Company and Mr. Meline (or any of his immediate family members) requiring disclosure under Item 404(a) of Regulation S-K. Mr. Meline does not have any family relationships with any of the Company’s directors or executive officers. Mr. Meline will participate in the Company’s non-employee director compensation policy, as described in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 13, 2023. In addition, the Company will enter into its standard form of indemnification agreement with Mr. Meline.
ITEM 7.01. REGULATION FD DISCLOSURE.
On October 16, 2023, the Company issued a press release relating to the appointment of Mr. Meline, a copy of which is furnished herewith as Exhibit 99.1 and incorporated herein by reference.
The information furnished in this Item 7.01 and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
| (d) | Exhibits. | ||||
| 99.1 | |||||
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) | ||||
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Pacific Biosciences of California, Inc. | ||||||||
| By: | /s/ Michele Farmer | |||||||
| Michele Farmer | ||||||||
| Vice President and Chief Accounting Officer | ||||||||
| Date: October 16, 2023 | ||||||||
PacBio Announces Appointment of David Meline to Board of Directors
Former CFO of Moderna, Amgen, and 3M Brings Decades of Relevant Experience to the PacBio Board
MENLO PARK, Calif., Oct. 16, 2023 /PRNewswire/ – PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Meline to its Board of Directors, effective October 13, 2023. Mr. Meline was most recently the Chief Financial Officer of Moderna, Inc., a global biotechnology and pharmaceutical leader.
“David is a highly respected executive with an extensive track record for leading companies in several industries through periods of extraordinary growth,” said Christian Henry, President and Chief Executive Officer of PacBio. “His experience, from leading Moderna through its transformational stage to scaling global organizations like Amgen and 3M, makes him an ideal addition to our board. I look forward to leveraging his deep experience as we continue scaling PacBio.”
Prior to Moderna, Mr. Meline served as the Chief Financial Officer for Amgen Inc. from 2014 to 2020 and 3M Company from 2008 to 2014, and spent more than 20 years at General Motors Company in various finance and management roles. Mr. Meline currently serves on the boards of directors of ABB Ltd., a publicly traded technology company specializing in electrification, motion and automation solutions, and the Los Angeles Philharmonic. Mr. Meline will join the board of directors of HP Inc. effective November 1, 2023. Mr. Meline holds a Bachelor’s degree in Mechanical Engineering from Iowa State University, a Master’s degree in Economics from the London School of Economics and Political Science, and a Master’s degree in Business Administration from the University of Chicago.
“I am thrilled to join the PacBio Board at this pivotal stage,” said Mr. Meline. “I’ve dedicated the latter part of my career to leading healthcare organizations that leveraged the power of genomics to develop some of the most groundbreaking therapies, so naturally, PacBio’s mission resonated with me. I believe the industry has only scratched the surface on how genomics can transform human health and am eager to help guide the company as it executes this mission.”
About PacBio
Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that is designing, developing and manufacturing advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality and completeness which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit www.pacb.com and follow @PacBio.
PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.
Contacts
Investors:
Todd Friedman
ir@pacificbiosciences.com
Media:
Lizelda Lopez
pr@pacificbiosciences.com